Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

Patients diagnosed with polycythemia vera currently have more specialized treatment options that may lead to improved responses to therapy, an expert said. Dr. Jamile M. Shammo, professor of medicine ...

Polycythemia vera (PV), which is marked by an increased number of red blood cells, is a rare blood cancer known to be associated with a high risk of cardiovascular disease. Median survival is ...

Yesterday the FDA approved Jakafi (Ruxolitinib), a pill, for use in treating polycythemia vera (p. vera). The drug, a targeted kinase inhibitor manufactured by Incyte, offers a needed option for some ...

Lipid Profiles Improved in Past Two Decades in United States For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of (HealthDay News) – For patients with ...

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG ...

The 7MM Polycythemia Vera market size reached approximately USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Polycythemia Vera pipeline constitutes 8+ key companies continuously working towards developing 10+ Polycythemia Vera ...

Protagonist Therapeutics, Inc. is progressing with the use of its drug rusfertide for the treatment of polycythemia vera in a phase 3 study. The company expects to complete enrollment of the VERIFY ...

Author(s)Paranagama D, Colucci P, Evans KA, Bonafede M, Parasuraman S. Are patients with high-risk polycythemia vera receiving cytoreductive medications? a retrospective analysis of real-world data.